| scholarly article | Q13442814 |
| P2093 | author name string | J. D. Curb | |
| P2860 | cites work | Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study | Q73134585 |
| Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity | Q73440398 | ||
| In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II | Q78476856 | ||
| Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins | Q24336646 | ||
| Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels | Q24562095 | ||
| Atherosclerosis | Q24644573 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study | Q28212472 | ||
| Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study | Q28216693 | ||
| The Cardiovascular Health Study: design and rationale | Q29614874 | ||
| Physical activity in older middle-aged men and reduced risk of stroke: the Honolulu Heart Program | Q30466518 | ||
| Plasma high density lipoproteins. Metabolism and relationship to atherogenesis | Q34257420 | ||
| Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years | Q34312337 | ||
| Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction | Q35763711 | ||
| Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene | Q35765195 | ||
| High-density lipoprotein--the clinical implications of recent studies | Q38700033 | ||
| High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. | Q39402383 | ||
| Serum Lipoproteins and Coronary Heart Disease in a Population Study of Hawaii Japanese Men | Q39969786 | ||
| HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study | Q40057178 | ||
| Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport | Q40845303 | ||
| A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits | Q40866383 | ||
| High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein | Q41733901 | ||
| A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction | Q43603017 | ||
| Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease | Q43929837 | ||
| Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics | Q44707696 | ||
| Hypercholesterolemia predicts early death from coronary heart disease in elderly men but not women. The Rancho Bernardo Study | Q46659891 | ||
| Analysis of covariance and standardization as instances of prediction. | Q52715986 | ||
| A Low Prevalence of Coronary Heart Disease among Subjects with Increased High-Density Lipoprotein Cholesterol Levels, Including Those with Plasma Cholesteryl Ester Transfer Protein Deficiency | Q61962950 | ||
| Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx Aging Study | Q68090012 | ||
| High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study | Q68359938 | ||
| Ascertainment of men of Japanese ancestry in Hawaii through World War II Selective Service registration | Q71624519 | ||
| Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase | Q71799205 | ||
| A mouse model with features of familial combined hyperlipidemia | Q71970948 | ||
| Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins | Q72410988 | ||
| P6195 | funding scheme | extramural research | Q124503498 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| heart disease | Q190805 | ||
| cardiovascular disease | Q389735 | ||
| coronary artery disease | Q844935 | ||
| age group | Q42401304 | ||
| age factor | Q64705711 | ||
| P5008 | on focus list of Wikimedia project | Wikimedia–NIOSH collaboration | Q104416361 |
| P304 | page(s) | 948-953 | |
| P577 | publication date | 2004-02-16 | |
| P1433 | published in | Journal of Lipid Research | Q6295449 |
| P859 | sponsor | NIOSH Health Effects Laboratory Division | Q123344455 |
| P1476 | title | A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly | |
| P478 | volume | 45 |
| Q50580181 | A novel microdeletion affecting the CETP gene raises HDL-associated cholesterol levels. |
| Q37688500 | ABC transporters, atherosclerosis and inflammation |
| Q37456662 | Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study |
| Q29999973 | Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction |
| Q51730433 | Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents. |
| Q33639433 | Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community |
| Q42107210 | Biochemical characterization of cholesteryl ester transfer protein inhibitors |
| Q34109100 | CETP inhibitors and cardiovascular disease: Time to think again |
| Q58791389 | Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action |
| Q34581693 | Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study |
| Q38832478 | Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations |
| Q34628218 | Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors |
| Q37765864 | Cholesteryl ester transfer protein and its inhibition |
| Q34253290 | Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk |
| Q38832774 | Cholesteryl ester transfer protein inhibitors: challenges and perspectives |
| Q30436835 | Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men. |
| Q33590777 | Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors |
| Q37864609 | Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles. |
| Q37179542 | Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis |
| Q37343533 | Concentration polarization of high-density lipoprotein and its relation with shear stress in an in vitro model |
| Q33577236 | Dalcetrapib: a review of Phase II data |
| Q47708252 | Design, Synthesis and Biological Evaluation of N,N-Substituted Amine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors. |
| Q47431168 | Design, Synthesis, and Biological Evaluation of N,N-Disubstituted-4-Arylthiazole-2-Methylamine Derivatives as Cholesteryl Ester Transfer Inhibitors. |
| Q36916850 | Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective |
| Q35895453 | Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics |
| Q87584832 | Dusty punch cards and an eternal enigma: high-density lipoproteins and atherosclerosis |
| Q38773023 | Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy |
| Q37511032 | Dyslipidemia and cardiovascular disease: a series of epidemiologic studies in Japanese populations |
| Q37481465 | Effects of the Cynanchum wilfordii Ethanol Extract on the Serum Lipid Profile in Hypercholesterolemic Rats |
| Q38229263 | Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials |
| Q38293506 | Emerging small molecule drugs |
| Q33993060 | Genetic causes of high and low serum HDL-cholesterol |
| Q35675097 | Genetic determinants of exceptional human longevity: insights from the Okinawa Centenarian Study |
| Q28469271 | Genetic determinants of human health span and life span: progress and new opportunities |
| Q36058450 | HDL as a target in the treatment of atherosclerotic cardiovascular disease |
| Q24323992 | HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway |
| Q36796655 | HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications |
| Q42151577 | HDL proteomics: pot of gold or Pandora's box? |
| Q34493756 | High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity |
| Q36503521 | Human genetics of variation in high-density lipoprotein cholesterol |
| Q37707402 | Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target? |
| Q35856905 | Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein |
| Q46901297 | Is elevated high-density lipoprotein cholesterol always good for coronary heart disease? |
| Q37351659 | Is high HDL cholesterol always good? |
| Q28294797 | JTT-705: is there still future for a CETP inhibitor after torcetrapib? |
| Q96132907 | Low Vitamin D Serum Level Is Associated with HDL-C Dyslipidemia and Increased Serum Thrombomodulin Levels of Insulin-Resistant Individuals |
| Q90273319 | Maternal plasma lipid levels across pregnancy and the risks of small-for-gestational age and low birth weight: a cohort study from rural Gambia |
| Q42772203 | Measuring the impact of nutrition education and physical activity on older adults participating in government sponsored programs |
| Q36716433 | Mechanisms of disease: HDL metabolism as a target for novel therapies |
| Q91708919 | Metrnl deficiency decreases blood HDL cholesterol and increases blood triglyceride |
| Q34102781 | Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol |
| Q35191066 | Molecular regulation of HDL metabolism and function: implications for novel therapies |
| Q34441411 | Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. |
| Q38293457 | Mouse models of disturbed HDL metabolism |
| Q34297063 | Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B) |
| Q37987207 | On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors |
| Q36971289 | Origins of intestinal ABCA1-mediated HDL-cholesterol |
| Q35928736 | Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein-1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease. |
| Q36197709 | Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib |
| Q24649155 | Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study |
| Q27011500 | Prevention of fatal hepatic complication in schistosomiasis by inhibition of CETP |
| Q38784846 | Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease |
| Q42824183 | Putting cholesterol in its place: apoE and reverse cholesterol transport |
| Q37068628 | Rapid regression of atherosclerosis: insights from the clinical and experimental literature |
| Q34120778 | Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial |
| Q36469056 | Serum lipid profile of newly diagnosed hypertensive patients in nnewi, South-East Nigeria |
| Q39962585 | The Relationship between Very High Levels of Serum High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in a 20-Year Follow-Up Study of Japanese General Population. |
| Q38780552 | The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel? |
| Q58130726 | The effects of curcumin and a modified curcumin formulation on serum Cholesteryl Ester Transfer Protein concentrations in patients with metabolic syndrome: A randomized, placebo-controlled clinical trial |
| Q37369256 | The hypertension peril: lessons from CETP inhibitors |
| Q38554684 | The potential of cholesteryl ester transfer protein as a therapeutic target |
| Q28249333 | The role of CETP inhibition in dyslipidemia |
| Q41867827 | The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. |
| Q36265996 | Torcetrapib/atorvastatin combination therapy |
| Q38201721 | Treating low high-density lipoprotein cholesterol: what is the evidence? |
| Q28085611 | Unique features of high-density lipoproteins in the Japanese: in population and in genetic factors |
Search more.